PEN

Penumbra
NYSE

Real-time Quotes | Nasdaq Last Sale

171.15
+1.53
+0.90%
After Hours: 167.00 -4.15 -2.42% 17:22 05/27 EDT
OPEN
169.49
PREV CLOSE
169.62
HIGH
171.76
LOW
161.11
VOLUME
204.49K
TURNOVER
--
52 WEEK HIGH
194.93
52 WEEK LOW
121.80
MARKET CAP
6.00B
P/E (TTM)
165.14
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PEN stock price target is 199.75 with a high estimate of 214.00 and a low estimate of 180.00.

EPS

PEN News

More
Penumbra Reports Launch Of $100M Common Stock Offering
Benzinga · 8h ago
Penumbra, Inc. Announces Launch of Offering of $100,000,000 of Shares of its Common Stock
Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares of common stock to be sold in the of
PR Newswire · 8h ago
IPO Update: Inari Medical Proposes IPO Terms
Seeking Alpha - Article · 05/18 18:15
Penumbra, Inc. Announces Virtual 2020 Annual Meeting of Stockholders
PR Newswire · 05/15 21:05
Penumbra Announces Management Transition
PR Newswire · 05/12 21:05
Penumbra, Inc. (PEN) CEO Adam Elsesser on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/10 04:10
JP Morgan Maintains Overweight on Penumbra, Raises Price Target to $200
JP Morgan maintains Penumbra (NYSE:PEN) with a Overweight and raises the price target from $175 to $200.
Benzinga · 05/08 16:22
Citigroup Maintains Buy on Penumbra, Raises Price Target to $214
Citigroup analyst Joanne Wuensch maintains Penumbra (NYSE:PEN) with a Buy and raises the price target from $192 to $214.
Benzinga · 05/08 11:23

Industry

Medical Equipment, Supplies & Distribution
+0.74%
Healthcare Equipment & Supplies
+0.73%

Hot Stocks

Symbol
Price
%Change

About PEN

Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
More

Webull offers kinds of Penumbra Inc stock information, including NYSE:PEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PEN stock news, and many more online research tools to help you make informed decisions.